White Paper

Insights On Clinical Trial Enrollment: Where We Are As We Head Into 2022

Source: Medidata AI
doctor clinical trial meeting iStock-986569806

The last two years have brought tremendous change and rapid innovation to the life sciences industry. Yet, patient enrollment persists as a critical challenge for sponsors and CROs. Currently, 80% of trials do not enroll within target enrollment timeframes and 55% of terminated trials cite low patient accrual as the main reason. 1, 2

Since 2020, the life sciences industry faced unprecedented challenges as COVID-19 put traditional clinical trial modalities to the ultimate test. As the effects of the pandemic fluctuated, Medidata continued to monitor clinical trial developments in a series of research reports.3 A year after our last report, we look back to assess the continued impact of the pandemic on clinical trial enrollment to help the industry navigate the dynamic landscape as we enter 2022. For the purpose of this analysis, we focus on Phase II and III studies across four therapeutic areas (TAs).

After multiple waves of new cases, the emergence of variants, and the rollout of mass vaccination campaigns, the COVID-19 pandemic continues to negatively affect clinical trial enrollment. The impact on enrollment rates varies across TAs and geographies, with some leading in recovery toward pre-pandemic levels, while others lag behind.

VIEW THE WHITE PAPER!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader